Skip to main content
Johnson & JohnsonAcquisition

Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.3 Billion

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.

What happened

Johnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront and up to approximately $1.1 billion in milestone payments.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Johnson & Johnson has agreed to acquire Ollin Biosciences , a privately held clinical-stage biotechnology company developing treatments for serious retinal diseases, for $2.2 billion upfront and up to approximately $1.1 billion in additional regulatory and commercial milestone payments. The transaction, which could reach approximately $3.3 billion if all milestones are achieved, is expected to close by the end of 2026, subject to regulatory approvals and customary closing conditions. The acquisition would give Johnson & Johnson control of Ollin's lead drug candidate, OLN324, an investigational bispecific antibody currently in Phase 3 development for wet age-related macular degeneration (AMD) and diabetic macular edema. OLN324 is designed to target vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), two proteins involved in abnormal blood vessel growth and leakage in retinal diseases. The therapy is being developed with optimized molecular size and potency to potentially improve treatment outcomes. Wet AMD and diabetic macular edema collectively affect more than 40 million people worldwide and are among the leading causes of vision loss. Ollin has reported proof-of-concept clinical data suggesting OLN324 could improve retinal anatomy, although the therapy remains investigational. Founded in 2023, Ollin was established to acquire and advance ophthalmology drug...

Keep reading with a free account

The rest of this article, and every signal for Johnson & Johnson, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Acquisition

What this signalsIntegration work after a deal often opens needs for new systems and services.

Companies

  • Ollin BiosciencesTargetollin.bio

More acquisition signals at other companies

The full record

From the Signal API record

Numbers

Amount (USD)
$3.3B

Extraction

Confidence
95%
Detected
Nov 16, 2026
signal_type
news
signal_subtype
acquires

Use this data

Get every acquisition signal for Johnson & Johnson and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”

  2. Send it to your own tools

    The Signal API returns acquisition signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b7fb724a-7db4-5669-04e4-f7565cd7f57c returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.

{
  "signal_id": "b7fb724a-7db4-5669-04e4-f7565cd7f57c",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-11-16T19:52:40+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.citybiz.co/article/934111/johnson-johnson-to-acquire-ollin-biosciences-for-up-to-3-3-billion/",
    "title": "Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.3 Billion - citybiz",
    "excerpt": "Johnson & Johnson has agreed to acquire Ollin Biosciences , a privately held clinical-stage biotechnology company developing treatments for serious retinal diseases, for $2.2 billion upfront and up to approximately $1.1 billion in additional regulatory and commercial milestone payments. The transaction, which could reach approximately $3.3 billion if all milestones are achieved, is expected to close by the end of 2026, subject to regulatory approvals and customary closing conditions. The acquisition would give Johnson & Johnson control of Ollin’s lead drug candidate, OLN324, an investigational bispecific antibody currently in Phase 3 development for wet age-related macular degeneration (AMD) and diabetic macular edema. OLN324 is designed to target vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), two proteins involved in abnormal blood vessel growth and leakage in retinal diseases. The therapy is being developed with optimized molecular size and potency to potentially improve treatment outcomes. Wet AMD and diabetic macular edema collectively affect more than 40 million people worldwide and are among the leading causes of vision loss. Ollin has reported proof-of-concept clinical data suggesting OLN324 could improve retinal anatomy, although the therapy remains investigational. Founded in 2023, Ollin was established to acquire and advance ophthalmology drug...",
    "summary": "Johnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront and up to approximately $1.1 billion in milestone payments.",
    "planning": true,
    "image_url": "https://www.citybiz.co/wp-content/uploads/2026/11/Ollin.jpg",
    "confidence": 0.95,
    "published_at": "2026-11-16T19:52:40Z",
    "article_sentence": "Johnson & Johnson has agreed to acquire Ollin Biosciences , a privately held clinical-stage biotechnology company developing treatments for serious retinal diseases, for $2.2 billion upfront and up to approximately $1.1 billion in additional regulatory and commercial milestone payments.",
    "amount_normalized": 3300000000,
    "related_company_name": "Ollin Biosciences",
    "related_company_domain": "ollin.bio"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.